The Future of Melanoma: What to Anticipate in 2023 with Neoadjuvant and Adjuvant Pembrolizumab
The Future of Melanoma: What to Anticipate in 2022Подробнее
WCH23: What’s New and Hot in MelanomaПодробнее
#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801Подробнее
Highlights in melanoma at AACR 2023Подробнее
AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey WeberПодробнее
Neoadjuvant Therapy and Adjuvant Therapy (pre and post-surgery) for MelanomaПодробнее
Advances in utilizing neoadjuvant immunotherapy in melanomaПодробнее
Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022Подробнее
Melanoma | 2022 OneOncology ConferenceПодробнее
NADINA: promising neoadjuvant immunotherapy strategies for melanomaПодробнее
Emerging Melanoma Therapies & Clinical Trials to WatchПодробнее
The future of adjuvant therapy in melanomaПодробнее
Results from the KEYNOTE-716: Pembrolizumab versus placebo after complete resection of high-risk...Подробнее
Updates in Melanoma: 2023 West OncologyПодробнее
Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanomaПодробнее
KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanomaПодробнее
How Melanoma is Treated in 2023Подробнее
The personalization of neoadjuvant immunotherapy in stage III melanomaПодробнее
KEYNOTE-716: adjuvant pembrolizumab for high-risk melanomaПодробнее